Ikena Oncology

Ikena Oncology, Inc. is a clinical stage biotechnology company. It discovers and develops patient directed, biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412 and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ikena Oncology, Inc. is a clinical stage biotechnology company, which engages in the development of patient directed and biomarker driven therapies for cancer patients. Its product pipeline includes IK-930, RAS Signaling, IK-175, IK-412, and IK-007. The company was founded by Mark Manfredi and George Georgiou in February 2016 and is headquartered in Boston, MA.

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA), a targeted oncology company focused on developing therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced financial results for the quarter ended March 31, 2021. “This first quarter marked important milestones for Ikena, both with our entrance into the public markets and the advances we have made across our pipeline. We continued to progress our clinical development programs and our l

Ikena Oncology Reports First Quarter 2021 Financial Results and Outlines Key Corporate Objectives for 2021

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the appointment of Maria Koehler, M.D., Ph.D. to its Board of Directors. Dr. Koehler is a board-certified hematologist and oncologist with more than 20 years of pharmaceutical and biotech oncology experience in clinical development, including senior roles at Pfize

Ikena Oncology Appoints Dr. Maria Koehler to its Board of Directors

180 Life Sciences 

Evelo Biosciences Inc

Ikena Oncology, Inc. (NASDAQ: IKNA), 180 Life Sciences Corp. (NASDAQ: ATNF) and Evelo Biosciences, Inc. (NASDAQ: EVLO) are among the major biopharma movers of Monday. Ikena Oncology Gains On Fund Buying: Ikena Oncology, which listed its shares on the Nasdaq on March 26 following an initial public offering of 7.8125 million shares at $16 apiece, disclosed in a 13G filing, Citadel Advisors beneficially owned about 2,053,068 shares or a 6.6% stake in the company.

Why Ikena Oncology, Evelo Biosciences And 180 Life Sciences Are Rallying Today

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (Nasdaq: IKNA) (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the closing of its initial public offering of 8,984,375 shares of common stock, including the exercise in full by the underwriters of their option to purchase up to 1,171,875 additional shares of common stock, at a public offering price of $16.00 per share. The ag

Ikena Oncology Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters' Option to Purchase Additional Shares

The stock price of Ikena Oncology Inc (NASDAQ: IKNA) increased by over 102% during intraday trading in its public debut today. These are the details.

IKNA Stock Price Increased Over 102% In Public Debut Intraday

BOSTON--(BUSINESS WIRE)--Ikena Oncology, Inc. (“Ikena”), a targeted oncology company focused on developing cancer therapies targeting key signaling pathways that drive the formation and spread of cancer, today announced the pricing of its initial public offering of 7,812,500 shares of common stock at a public offering price of $16.00 per share. The shares are expected to begin trading on the Nasdaq Global Market on March 26, 2021 under the ticker symbol “IKNA.” The gross proceeds of the offerin

Ikena Oncology Announces Pricing of Initial Public Offering

Ikena Oncology has filed to raise $125 million in a U.S. IPO. The company is developing treatment candidates for various cancers.

Ikena Oncology Aims For $125 Million IPO

News for Ikena Oncology Stock (IKNA)